Serial Number | 97187298 |
Word Mark | S |
Filing Date | Thursday, December 23, 2021 |
Status | 606 - ABANDONED - NO STATEMENT OF USE FILED |
Status Date | Monday, November 18, 2024 |
Registration Number | 0000000 |
Registration Date | NOT AVAILABLE |
Mark Drawing | 3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
Published for Opposition Date | Tuesday, August 22, 2023 |
Description of Mark | The mark consists of a stylized S in the shape of a swan's wing. |
Goods and Services | Therapeutic pharmaceutical compositions comprised of adeno-associated viral (AAV) vectors and recombinant adeno-associated viral (rAAV) vectors for therapeutic effect in gene therapy, namely, gene inhibition therapy and/or RNA interference (RNAi), for the treatment of genetic diseases and disorders and neurological diseases and disorders; therapeutic pharmaceutical compositions comprised of adeno-associated viral (AAV) vectors and recombinant adeno-associated viral (rAAV) vectors for therapeutic effect in gene therapy, namely, gene augmentation therapy, for the treatment of genetic diseases and disorders and neurological diseases and disorders; therapeutic pharmaceutical compositions comprised of adeno-associated viral (AAV) vectors and recombinant adeno-associated viral (rAAV) vectors for therapeutic effect in gene therapies using intrathecal administration, for the treatment of genetic diseases and disorders and neurological diseases and disorders; biologic preparations for use in the treatment of genetically based diseases and disorders; biologic preparations for medical purposes, namely, for gene therapy for treating genetic disorders; pharmaceutical preparations that modulate RNA expression for the treatment of neurological diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; gene therapy products, namely, gene delivery pharmaceuticals for the treatment of genetic diseases and disorders and neurological diseases and disorders; pharmaceutical preparations for gene therapy, gene inhibition and gene augmentation, for the treatment of genetic diseases and disorders and neurological diseases and disorders; viruses, viral vectors and viral constructs, all in the nature of pharmaceutical preparations, for the treatment of neurological diseases and disorders and genetic diseases and disorders; pharmaceutical preparations for gene therapy, for the treatment of genetic diseases and disorders and neurological diseases and disorders; pharmaceutical and biopharmaceutical agents for the treatment of genetic disorders and neurological diseases and disorders; pharmaceutical preparations, namely, nucleic acid therapeutics for the treatment of genetic disorders and neurological diseases and disorders; pharmaceutical preparations, namely, DNA and/or RNA therapeutics for the treatment of genetic disorders and neurological diseases and disorders |
Goods and Services | Development of pharmaceutical preparations for use in gene therapy; genetic engineering and biotechnology research; research and development of new products in the field of gene therapeutics; scientific and medical research in the field of genetics, gene therapy and genetic engineering; laboratory research in the fields of genetics, gene therapy, drug development, biotechnology, microbiology and molecular biology; pharmaceutical drug discovery; scientific research in the field of gene therapy discovery; drug development and therapeutic drug development; genetic drug development and therapeutic drug development; biological research; biological drug development and scientific research in the field of biological development |
International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
Class Status Code | 6 - Active |
Class Status Date | Friday, January 14, 2022 |
Primary Code | 005 |
First Use Anywhere Date | NOT AVAILABLE |
First Use In Commerce Date | NOT AVAILABLE |
International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
US Class Codes | 100, 101 |
Class Status Code | 6 - Active |
Class Status Date | Friday, January 14, 2022 |
Primary Code | 042 |
First Use Anywhere Date | Monday, March 15, 2021 |
First Use In Commerce Date | Monday, March 15, 2021 |
Party Name | SwanBio Therapeutics Limited |
Party Type | 20 - Owner at Publication |
Legal Entity Type | 99 - Other |
Address | Bala Cynwyd, PA 19004 |
Party Name | SwanBio Therapeutics Limited |
Party Type | 10 - Original Applicant |
Legal Entity Type | 99 - Other |
Address | Bala Cynwyd, PA 19004 |
Event Date | Event Description |
Friday, January 14, 2022 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
Saturday, January 15, 2022 | NOTICE OF DESIGN SEARCH CODE E-MAILED |
Tuesday, September 27, 2022 | ASSIGNED TO EXAMINER |
Wednesday, October 12, 2022 | NON-FINAL ACTION WRITTEN |
Wednesday, October 12, 2022 | NON-FINAL ACTION E-MAILED |
Wednesday, October 12, 2022 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
Monday, April 10, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
Monday, April 10, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
Monday, April 10, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
Friday, May 19, 2023 | FINAL REFUSAL WRITTEN |
Friday, May 19, 2023 | FINAL REFUSAL E-MAILED |
Friday, May 19, 2023 | NOTIFICATION OF FINAL REFUSAL EMAILED |
Thursday, June 29, 2023 | TEAS REQUEST FOR RECONSIDERATION RECEIVED |
Thursday, June 29, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
Thursday, June 29, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
Wednesday, July 19, 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
Wednesday, August 2, 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
Tuesday, August 22, 2023 | PUBLISHED FOR OPPOSITION |
Tuesday, August 22, 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
Tuesday, October 17, 2023 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
Thursday, April 11, 2024 | SOU EXTENSION 1 GRANTED |
Thursday, April 11, 2024 | SOU TEAS EXTENSION RECEIVED |
Thursday, April 11, 2024 | SOU EXTENSION 1 FILED |
Friday, April 12, 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
Monday, November 18, 2024 | ABANDONMENT - NO USE STATEMENT FILED |
Monday, November 18, 2024 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |